You are here

Better Health Literacy Seems To Boost Patient Satisfaction With Biosimilars

European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.

European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.

There seems to be a relationship between a patient’s willingness to switch to a biosimilar and health literacy, according to study presented by Milada Cvancarova Smastuen and colleagues at the European League Against Rheumatism’s Annual European Congress of Rheumatology in June in Amsterdam. About one in five patients taking etanercept (Enbrel) or infliximab (Remicade) who were switched to less expensive biosimilars said that they were dissatisfied. But the study adds that the patients’ level of satisfaction with the switch was associated with health literacy, which researchers defined as being given sufficient and necessary information about their health.

Source: Center for Biosimilars

More Headlines

First Once-Daily, Nebulized Bronchodilator Available at End of 2018
AI Software Helps Physicians Prioritize Patients with Hemorrhagic Stroke or Intracranial Trauma
Empagliflozin Could Help Prevent Heart Disease and Heart Failure
Combination of Experimental Drug and Checkpoint Inhibitors Fight Tumor Cells
Zulresso May Alleviate Symptoms for Thousands of Women
Developed for Tumors Resistant to Other TKIs
New Drug Reduces Infection in Chemotherapy Patients
Daily Use of AHCC Supplement Could Support Immune System, Eliminate HPV
Unique Bio-Identical Hormone Therapy for Treatment of Hot Flashes